Oruka Therapeutics, Inc. ORKA Cash, cash equivalents and short-term investments
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents.
The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Questions, answered.
- What is Oruka Therapeutics, Inc.'s cash, cash equivalents and short-term investments?
- Oruka Therapeutics, Inc. (ORKA) reported cash, cash equivalents and short-term investments of $4.94M in Q3 2024.